Get the Stockscreener App
5.11
3.23%
0.16
After Hours:
5.13
0.02
+0.39%
Bolt Biotherapeutics Inc stock is traded at $5.11, with a volume of 9,033.
It is up +3.23% in the last 24 hours and up +5.80% over the past month.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
See More
Previous Close:
$4.95
Open:
$4.89
24h Volume:
9,033
Relative Volume:
0.37
Market Cap:
$9.82M
Revenue:
$7.70M
Net Income/Loss:
$-33.38M
P/E Ratio:
-0.415
EPS:
-12.3134
Net Cash Flow:
$-39.92M
1W Performance:
+8.26%
1M Performance:
+5.80%
6M Performance:
+3.23%
1Y Performance:
-20.65%
1-Day Range:
$4.89
$5.135
1-Week Range:
$4.30
$5.135
52-Week Range:
$3.91
$7.35
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Name
Bolt Biotherapeutics Inc
Sector
Industry
Phone
650-665-9295
Address
900 CHESAPEAKE DRIVE, REDWOOD CITY
Compare BOLT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
5.11 | 9.51M | 7.70M | -33.38M | -39.92M | -12.31 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Resumed | H.C. Wainwright | Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-02-21 | Initiated | Guggenheim | Buy |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
View All
Bolt Biotherapeutics Inc Stock (BOLT) Latest News
Bolt Biotherapeutics, Inc. (BOLT) reports Q1 loss, lags revenue estimates - MSN
Bolt Biotherapeutics, Inc.Common Stock (NQ: BOLT - The Chronicle-Journal
Bolt Biotherapeutics: Cash on Hand Is Expected to Fund Ops Into 2027 - Moomoo
Press Release: Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results - TradingView
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot - marketscreener.com
Bolt Biotherapeutics 1Q 2026: Revenue $26K, Net loss $7.24M, EPS $(4.31) — 10-Q Summary - TradingView
Bolt Biotherapeutics (NASDAQ: BOLT) narrows Q1 loss, cuts expenses - Stock Titan
Cancer drug trial data due in 3Q 2026 as Bolt logs $7.6M operating loss - Stock Titan
BOLT (Bolt Bio) beats earnings estimates as quarterly loss narrows 38 percent, but stock flat.Asset Sale - newser.com
Bolt Biotherapeutics Inc expected to post a loss of $2.85 a shareEarnings Preview - TradingView
BOLT Q1'26 Earnings: EPS estimate is (2.85) USD - TradingView
Bolt Biotherapeutics (BOLT) 2026 proxy details director votes and auditor - Stock Titan
[ARS] Bolt Biotherapeutics, Inc. SEC Filing - Stock Titan
Is Bolt Bio (BOLT) stock moving unpredictably (Trend Strengthens) 2026-04-20Community Pattern Alerts - Cổng thông tin điện tử Tỉnh Sơn La
Operating cash flow per share of Bolt Biotherapeutics, Inc. – MUN:6LP0 - TradingView
Aug Movers: Is Bolt Biotherapeutics Inc still a buy after recent gainsMarket Activity Summary & Verified Momentum Stock Ideas - baoquankhu1.vn
Treasury Yields: Will Bolt Biotherapeutics Inc announce a stock splitWeekly Loss Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn
What is the price target for Bolt Bio (BOLT) Stock | Price at $4.75, Up 5.21%Verified Signals - Newser
BOLT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Is momentum building in Bolt Bio (BOLT) Stock | Price at $4.81, Up 0.63%Percent Below MA - Newser
Performance Recap: Is Bolt Biotherapeutics Inc still a buy after recent gains2026 Buyback Activity & Stepwise Swing Trade Plans - baoquankhu1.vn
Is Bolt Bio (BOLT) Stock Ready to Drop | Price at $4.56, Up 6.29%Crowd Sentiment Stocks - Newser
BOLT Uptrend Accelerates on Market - newser.com
Technical Analysis: Will Bolt Biotherapeutics Inc announce a stock splitTrade Exit Report & Community Consensus Stock Picks - baoquankhu1.vn
Sentiment Watch: Is Bolt Biotherapeutics Inc on track to beat earnings2026 Outlook & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Income Plays: Is Bolt Biotherapeutics Inc impacted by rising ratesEarnings Summary Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Entry Recap: Is Bolt Biotherapeutics Inc undervalued by DCF analysisInsider Selling & High Conviction Investment Ideas - baoquankhu1.vn
Institution Moves: What is the long term forecast for Bolt Biotherapeutics Inc stock2026 Price Action Summary & Growth Focused Entry Reports - baoquankhu1.vn
Fund Flows: Is Bolt Biotherapeutics Inc still a buy after recent gains2026 Breakouts & Weekly Return Optimization Alerts - baoquankhu1.vn
Aug Sectors: What are Bolt Biotherapeutics Incs earnings expectationsTrade Entry Report & AI Powered Market Entry Ideas - baoquankhu1.vn
Momentum Shift: Is Bolt Biotherapeutics Inc still a buy after recent gains2026 Institutional & Stepwise Trade Signal Guides - baoquankhu1.vn
Trend Recap: Will Bolt Biotherapeutics Inc outperform its industry peersWeekly Trade Analysis & Long Hold Capital Preservation Tips - baoquankhu1.vn
Bolt Biotherapeutics discloses new STING agonist immunoconjugates - BioWorld News
Bronstein, Gewirtz and Grossman, LLC sends a Class Action Lawsuit reminder to shareholder investors for Bolt Biotherapeutics, Inc. to Lead the Class Action Lawsuit! - ACCESS Newswire
CEO Change: Is Bolt Biotherapeutics Inc on track to beat earnings2026 Chart Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Bolt Biotherapeutics (BOLT) to Release Quarterly Earnings on Wednesday - Defense World
If You Invested $1,000 in Bolt Biotherapeutics, Inc. (BOLT) - Stock Titan
Buyout Rumor: Is Bolt Biotherapeutics Inc undervalued by DCF analysisInsider Buying & Technical Pattern Based Signals - baoquankhu1.vn
Market Outlook: Is Bolt Biotherapeutics Inc likely to announce a buybackEarnings Miss & Short-Term Swing Trade Alerts - baoquankhu1.vn
Market Leaders: Is Bolt Biotherapeutics Inc likely to announce a buyback2026 Action & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Sell Signal: Will Bolt Biotherapeutics Inc outperform its industry peersPortfolio Gains Summary & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
What is the long term forecast for Bolt Biotherapeutics Inc stock2026 News Drivers & Fast Gain Stock Tips - baoquankhu1.vn
Weekly Earnings: Is Bolt Biotherapeutics Inc stock a smart retirement pick2026 Bull vs Bear & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Fundamentals Check: Does Bolt Biotherapeutics Inc have strong EBITDA margins2026 Bull vs Bear & Community Consensus Trade Signals - baoquankhu1.vn
Whats the outlook for Bolt Biotherapeutics Incs sector2026 Analyst Calls & Long Hold Capital Preservation Plans - baoquankhu1.vn
Market Outlook: Is Bolt Biotherapeutics Inc stock a smart retirement pick2026 Weekly Recap & High Conviction Trade Alerts - baoquankhu1.vn
HC Wainwright Reiterates Buy Rating for Bolt Biotherapeutics (BO - GuruFocus
Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot - theheraldreview.com
Bolt Biotherapeutics Inc Stock (BOLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):